VRCA Earnings & Financial Statements
Verrica Pharmaceuticals Inc.
$4.20
+$0.06(+1.45%)
30
Overall
40
Value
10
Tech
42
Quality
Market Cap
$72.32M
Volume
9.83K
52W Range
$3.28 - $9.82
Target Price
$13.83
VRCA earnings and financial statements: Verrica Pharmaceuticals Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VRCA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $35.58M | $7.57M | $5.12M | $9.03M | $12.00M |
| Cost of revenue | $3.44M | $2.74M | $500.0K | $725.0K | - |
| Operating income | -$12.19M | -$65.92M | -$65.76M | -$21.30M | -$30.91M |
| EBITDA | -$9.40M | -$65.94M | -$67.73M | -$21.60M | -$30.31M |
| Net income | -$17.89M | -$76.58M | -$67.00M | -$24.49M | -$35.08M |
| EPS (diluted) | $-1.68 | $-14.80 | $-14.80 | $-7.20 | $-13.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $47.13M | $54.13M | $81.60M | $44.72M | $80.13M |
| Total liabilities | $22.39M | $63.99M | $61.83M | $4.69M | $47.52M |
| Shareholders’ equity | $24.74M | -$9.86M | $19.76M | $40.03M | $32.60M |
| Cash and equivalents | $30.10M | $46.33M | $69.55M | $34.27M | $15.75M |
| Long-term debt | $885.0K | $32.33M | $44.81M | $1.23M | $1.47M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$17.60M | -$60.93M | -$38.58M | -$18.65M | -$27.58M |
| Capital expenditure | - | -$19.0K | -$362.0K | -$302.0K | -$883.0K |
| Free cash flow | -$17.60M | -$60.95M | -$38.94M | -$18.95M | -$28.46M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VRCA | $4.20 | +1.4% | 9.83K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Verrica Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW